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Background: Immunotherapy has been widely used in the treatment of allergic 
diseases. We evaluated the clinical efficacy of specific immunotherapy with extracts 
of Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df) in chil-
dren with asthma.
Methods: All 40 children had moderate-to-severe asthma and positive allergen 
tests for Dp and Df. All required daily medication. They were randomly assigned to 
two groups: Half of them received immunotherapy with subcutaneous injections of 
Dp and Df extracts, while the other half were not given immunotherapy. Participants 
were followed up for more than 6 months.
Results: Children in both groups had apparent improvements in medication use and 
symptoms after 6 months. The mean medication scores declined from 3.6 ± 1.14 to 
1.7 ± 0.66 in the immunotherapy group (p < 0.01) and from 3.35 ± 0.87 to 2.4 ± 1.09 
in the control group (p < 0.01). There was a significant difference between the two 
groups (mean difference 0.95; p < 0.01). The symptom score improved in the immu-
notherapy group from 2.65 ± 0.98 to 1.20 ± 1.00 (p < 0.01) and in the control group 
from 2.55 ± 0.99 to 1.40 ± 0.88 (p < 0.01), with a significant difference between the 
two groups (mean difference 0.3; p < 0.01). The number of office visits in the immu-
notherapy group was greater than that of the controls, but the frequencies of 
emergency room visits and hospitalization decreased.
Conclusion: Our study showed that specific immunotherapy with Dp and Df was 
beneficial for asthmatic children.
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1.  Introduction
Immunotherapy using injected aeroallergen extracts 
was first evaluated for the treatment of seasonal 
pollinosis in 19111 and has been widely used as a 
treatment for respiratory allergies, especially al-
lergic rhinitis and asthma.2 Controlled trials have 
shown that immunotherapy, using high-quality ex-
tracts in sufficient doses, relieves the symptoms 
of allergic rhinoconjunctivitis with minimal side 
effects.3,4 Studies of immunotherapy for allergic 
asthma have shown that single-allergen immuno-
therapy reduces airway sensitivity to allergens, 
decreases symptoms and signs, and improves basal 
pulmonary function in some cases.5,6
Immunotherapy with crude extract or partially 
purified allergen has been used in adults with allergic 
asthma,7−9 however, controlled clinical trials in chil-
dren with allergic asthma have revealed no discerni-
ble benefits of multiple-antigen immunotherapy.10 
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Nevertheless, although specific immuno therapy (SIT) 
is recommended for adults with asthma in the Global 
Initiative for Asthma (GINA) guidelines, its therapeu-
tic role in children with asthma is still uncertain.11
House dust mites, especially Dermatophagoides 
pteronyssinus (Dp) and Dermatophagoides farinae 
(Df), have been shown to comprise the most im-
portant allergens in airway hypersensitivity,12 and 
are well known inhalant allergens responsible for 
certain Immunoglobulin E(IgE)-mediated disorders, 
such as allergic rhinitis and asthma.13 Available tests, 
including the skin prick test and specific antibody 
tests, can precisely detect reactions to Dp and Df in 
allergic children.14
The current study aims to evaluate the additive 
benefits of SIT using the specific injected allergens, 
Dp and Df, in allergic children with asthma who 
were receiving satisfactory medical care, including 
asthma pharmacotherapy.
2.  Materials and Methods
2.1.  Patients
We recruited 40 children (21 boys and 19 girls). All 
eligible children underwent an initial period of ob-
servation and had medical records for more than 1 
year with a diagnosis of moderate persistent to se-
vere persistent asthma, according to the severity 
classification of the GINA guidelines.11 During the 
year of observation, the children had daytime or 
nocturnal asthma symptoms and suffered from fre-
quent exacerbations. They also used daily asthma 
medications, including rapid-acting β2 agonists, 
either for prophylaxis or rescue use. The children 
and their parents were instructed on how to man-
age their asthma and were evaluated for medical 
compliance. All enrolled children were monosensi-
tized to house dust mites, as demonstrated by a skin 
prick test or specific antibody test. Enrolled chil-
dren and their parents were informed about the 
details and risks of treatment, and guardians of all 
the children provided signed informed consent.
2.2.  Management of asthma
At each visit, a team of clinical pediatricians, who 
were unaware of the treatment assignments, re-
viewed the patients’ daily diaries, including records 
of symptom scores, diurnal peak-flow readings, 
and medications. They administered the medical 
treatment to the children according to their indi-
vidual conditions of asthma control. The medication 
was increased or reduced by stepping up or down 
to gain control of clinical symptoms and/or lung 
function. Asthma medications were provided by 
national health insurance and adjusted in a stepwise 
fashion as follows: step 0, no need for medication; 
step 1, use of rapid-acting inhaled β2 agonist as 
needed; step 2, regular use of single medication such 
as low-dose inhaled corticosteroids (ICS), sustained-
release theophylline, or leukotriene modifier; step 
3, regular combined use of two drugs, such as low-
to-medium dose ICS plus long-acting β2 agonist, or 
medium-dose ICS plus sustained release theophyl-
line or leukotriene modifier; step 4, regular use of 
high-dose ICS plus long-acting β2 agonist, and ad-
ditional sustained release theophylline or leukotriene 
modifier; step 5, the use of oral corticoste-roids 
such as prednisolone. Acute exacerbations of 
asthma were treated by prescriptions from the 
children’s physicians. Emergency room care and 
inpatient treatment were provided at the physi-
cians’ discretion.
2.3.  Specific immunotherapy (SIT)
Allergies to Dp and Df were confirmed by skin prick 
or specific antibody tests prior to randomization. 
Children were divided randomly into two groups: 
an immunotherapy group and a control group. 
Children in the immunotherapy group received 
subcutaneous injections of extracts of Dp and Df 
(10,000 AU/mL, Allermed Laboratories Inc., San 
Diego, CA, USA), respectively, at an initial dose of 
0.5 AU/mL once a week. The dosage was increased 
weekly by 25−100% to reach an optimal maintenance 
dose. A large local reaction has previously been 
shown to predict a systemic reaction.15 If a dose 
produced a systemic reaction, the next dose was 
adjusted to 1/5 of the previous dose and was used as 
the optimal maintenance dose. Maintenance ther-
apy was given every 2 weeks for at least 3 months. 
Dosage adjustments and safety procedures were 
based on large local reactions or systemic reactions 
combined with the authors’ long-term experience 
and systematic attempts to rationalize the treat-
ment by identifying risk factors and improving 
safety, while balancing time consumption, patient 
inconvenience, and the risk of inducing systemic 
reactions.16
2.4.  Outcome variables
The principal outcome measure was the amount of 
medication required to control symptoms and main-
tain peak flows within acceptable limits. We used 
a 5-point ordinal scale of daily medication usage 
scores, modified according to the management of 
the GINA guideline.11 Briefly, a score of 0 indicated 
no medication; scores 1−4 reflected the respective 
steps 1−4 of the medical algorithm; and score 5 
reflected the use of systemic prednisolone.
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Secondary outcome measures included the daily 
peak expiratory flow rate, asthma symptom score,17 
and number of contacts with health care providers.
2.5.  Statistical analysis
Nonparametric statistics were used to determine 
p values for group comparisons of all outcome 
measures. In the subgroup analysis of daily medica-
tion use, we used rank transformation and two-way 
analysis of variance to determine if the effect of im-
munotherapy differed among subgroups of children. 
All p values reported were two-sided and were cal-
culated using SPSS version 14.0 (SPSS Inc., Chicago, 
IL, USA) and Excel software for the signed-rank 
test, rank-sum test, and analysis of variance.
3.  Results
3.1.  Patients
A total of 40 children (21 boys and 19 girls) were en-
rolled in the study. Their average age at randomi-
zation was 8.5 years, ranging from 5 to 14 years. The 
baseline characteristics did not differ significantly 
between the two treatment groups (Table 1).
3.2.  Primary outcomes
The mean daily medication scores before randomi-
zation (baseline) and 6 months later (last follow-up 
visit) are listed in Table 2. The mean score declined 
significantly from randomization to the last follow-up 
visit in both groups (p < 0.01). However, there were 
no significant between-group differences at base-
line or at the last follow-up visit.
We compared the mean change in medication 
scores between baseline and the last follow-up 
visit to identify any treatment-related changes in 
daily medication use. The magnitude of the changes 
was significant in the two groups (mean difference 
0.95, 95% CI −0.92 to −0.97; p < 0.01) (Table 2).
3.3.  Other outcomes
Other clinical outcomes are shown in Table 2. Both 
groups had significant reductions in symptom scores. 
The changes in both groups were significantly differ-
ent and were related to the different treatments 
Table 1  Characteristics of 40 children with allergic 
asthma randomly assigned to specific immu-
notherapy or control group
 Immunotherapy ControlCharacteristics
 (n = 20) (n = 20)
Mean age (yr) 8.6 ± 2.99 8.35 ± 2.43
Sex (M/F) 14/6 7/13
Symptom score 2.65 ± 0.98 2.55 ± 0.99
Medication score 3.60 ± 1.14 3.35 ± 0.87
Peak flow  83.15 ± 7.49 84.98 ± 5.50
 (% of predicted value)
Table 2 Changes in outcome measures from baseline to the last follow-up visit
Measure Immunotherapy (n = 20) Control (n = 20) Mean difference p
Medication score    
  Baseline 3.6 ± 1.14 3.35 ± 0.87 0.25 0.44
  Last follow-up 1.7 ± 0.66 2.4 ± 1.09 −0.7 0.02
  Change −1.90 −0.95 0.95 < 0.01
  p < 0.01 < 0.01  
Symptom score
  Baseline 2.65 ± 0.98 2.55 ± 0.99 0.1 0.75
  Last follow-up 1.20 ± 1.00 1.40 ± 0.88 −0.2 0.51
  Change −1.45 −1.15 0.3 < 0.01
  p < 0.001 < 0.01
PEFR (% of predicted value)
  Baseline 83.15 ± 7.49 84.98 ± 5.50 −1.83 0.39
  Last follow-up 84.3 ± 5.56 84.12 ± 4.72 0.18 0.92
  Change 1.15 −0.86 −2.01 −
  p 0.056 0.099
Medical contact (no. in 6 mo)
  Clinic visit 17.25 ± 4.6 12.4 ± 5.87 4.8 0.006
  Emergency room or hospitalization 0.76 ± 0.17 0.95 ± 0.21 −0.19 0.267
PEFR = peak expiratory flow rate.
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(mean difference 0.3, 95% CI 10.29 to −0.31; p < 0.01). 
The peak expiratory flow rate increased in the im-
munotherapy group but declined slightly in the 
control group, though the difference was not sig-
nificant. In summary, the immunotherapy group 
had a significantly greater improvement in symp-
toms than the control group. The immunotherapy 
group had a higher peak expiratory flow rate than 
the control group after treatment, but neither the 
differences before and after treatment, nor be-
tween groups were significant (Table 2).
3.4.  Treatment-related adverse events
The most common adverse effect was local, red-
dish swelling at the injection site, which was expe-
rienced by eight children in the immunotherapy 
group. There was no apparent systemic reaction to 
the injections in our study.
4.  Discussion
In this study, children with allergic asthma specific 
to Dp and Df were treated according to a protocol 
designed to approximate current standards for im-
munotherapy and pharmacotherapy. Immunotherapy 
using injections of specific allergen or allergens 
affected the course of asthma in children during 
the 6-month follow-up period, by decreasing their 
daily medication use and relieving symptoms.
These results are contrary to those of a previ-
ous study, where no discernible benefit of immu-
notherapy with injections of allergens in children 
with asthma already receiving pharmacotherapy 
was reported.7 Studies of subcutaneous SIT in chil-
dren have not been as numerous as those in adults, 
and their results have usually assigned this therapy 
a controversial role in pediatric asthma treatment. 
However, Adkinson et al7 used therapeutic extracts 
containing mixtures of up to seven allergens, in-
cluding pollen, molds, and dust mites. They pre-
sumed that dilution of multiple allergens may 
result in suboptimal doses of individual allergens, 
or mixtures with other allergens may reduce the 
potency of individual allergens. As a result, they 
suggested that the use of allergen mixtures be 
avoided. The current study showed beneficial re-
sults by utilizing mite-specific immunotherapy, but 
not allergen mixtures, indicating that SIT may be 
more appropriate for treating asthma in children 
than immunotherapy using mixtures of multiple 
allergens. Thus, our conclusions are different from 
those of the Adkinson et al study,7 but consistent 
with those from other recent reports.18
Although SIT has been used in the treatment of 
childhood asthma, the recommendations of this 
therapy have varied from cautious acceptance to 
outright dismissal. Both the European Academy of 
Allergy and Clinical Immunology and the British 
Society for Allergy and Clinical Immunology advised 
against its use in patients under 5 years of age, 
and raised doubts about its use for the treatment 
of pediatric asthma.4,19 Moreover, the National Heart, 
Lung, and Blood Institue Working Group and the 
World Health Organization stressed that SIT should 
be considered only in cases where exposure to al-
lergens cannot be avoided, or when a suitable 
pharmacological therapy has proved unable to 
control the disease.20 Immunotherapy was omitted 
from the recommended asthma treatment for chil-
dren, although it remains a choice of standard asthma 
treatment for adults.11 In our study, SIT had additive 
benefits and produced no marked side effects in the 
children, who were all above 5 years old and receiv-
ing suitable medical care. However, investigations 
and observations in larger populations are needed to 
further demonstrate the effectiveness of SIT.
In our study, SIT effectively reduced the medica-
tion requirements and symptoms in children with 
allergic asthma. However, while a trend towards bet-
ter performance was observed in the SIT group, the 
improvement in peak flow rate failed to reach statis-
tical significance. Some reports suggested that SIT 
may improve bronchial reactivity,6 while others re-
mained controversial. Immuno therapy provides the 
potential to downregulate the inflammatory 
cascade,21 reduce IgE antibody production,22,23 and 
attenuate symptoms in patients with asthma.24 If 
these patients are left untreated, they would un-
dergo airway remodeling and eventually progress to 
permanent abnormalities of the bronchial wall. Such 
remodeling processes are likely to play a considera-
ble role in lung function decline and bronchial 
obstruction.25,26 Conceptually, early intervention in 
allergic disease is the most promising strategy for ar-
resting disease progression, altering its severity, and 
preventing the development of the respiratory dis-
ease process.27−29 It could be reasonably supposed 
that early management with SIT in children with 
asthma may alleviate bronchial reactivity and even 
reverse bronchial obstruction before the natural pro-
gression to airway remodeling. Recent studies of SIT 
might support this possibility by demonstrating its 
long-term efficacy30 and its preventive effect in re-
ducing the onset of new sensitizations.31
A few children in our study experienced side ef-
fects of SIT with Dp and Df; eight children had 
local reddish swelling in injection site. It cannot 
be overemphasized that immunotherapy should be 
performed carefully because of the risk of side ef-
fects, which include itching, flushing, erythema, 
local swelling, urticaria, rhinitis, conjunctivitis, 
bronchospasm, and anaphylactic shock.32
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In conclusion, our results further support the 
idea that SIT using individual injections of extracts 
of house dust mites is effective in children with al-
lergic asthma, and can reduce medication use and 
alleviate asthma symptoms.
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